Please assess the completion status of the following clinical trial:

Trial Title: HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years~2. Cirrhosis defined by any one of the following~   1. Cirrhosis on liver biopsy or transient wave elastography~  2. Nodular liver on imaging~  3. Endoscopic or radiological evidence of varices in a patient with chronic liver disease~  4. Platelet count \<150,000/mm3 and AST/ALT ratio \>1 in a patient with chronic liver disease~  5. Patients with frank decompensation (ascites, HE, variceal bleeding, hepato-pulmonary syndrome)~3. Prior HE controlled on standard of care therapy defined as lactulose or rifaximin for at least 2 months prior to enrollment.~4. Serum albumin \<4 gm/dl~5. Cognitive impairment on any of the three testing strategies for HE including Psychometric hepatic encephalopathy score (PHES), Stroop test and Critical Flicker Frequency~   1. PHES aggregate score \<-4SD based on norms published in Allampati et al located at the website www.encephalapp.com~  2. Stroop OffTime+OnTime values greater than norms published in Allampati et al located at the website www.encephalapp.com~  3. Critical Flicker Frequency value \<39 Hz~Exclusion Criteria:~1. Unclear diagnosis of cirrhosis (does not meet the criteria outlined above)~2. No prior overt HE episodes~3. HE uncontrolled on standard of care defined as a mini-mental status exam\<25~4. On regular IV albumin infusions due to scheduled paracentesis within the last 3 months~5. Recent alcohol abuse (within 3 months)~6. Unable to give consent~7. Current or recent invasive bacterial or fungal infections (\<1 month)~8. Allergic reactions to IV albumin~9. Current or recent congestive heart failure (Systolic ejection fraction \<25%) within the last year~10. Pregnancy (positive urine pregnancy test at screening)~11. In the opinion of the PI, those who are unlikely to survive 6 weeks or be able to adhere to the trial activities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV albumin (Type: EXPERIMENTAL): 25% IV albutein (albumin) formulation will be infused 1.0g/kg IV over one hour weekly for 5 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline will be infused 1.0g/kg IV over one hour weekly for 5 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).